Watch the key takeaways in prostate cancer from ASCO20 Virtual by Professor Eric Small.

Do patients with non-metastatic castration-resistant prostate cancer exist or do they all have metastases if submitted to a PET scan? See Eric J. Small's MEDtalk and hear his thoughts on the matter.

Professor Martin Reck explains the background for CheckMate 9LA-study and the effect of the combination of nivolumab and ipilimumab + 2 cycles of chemotherapy as first-line treatment of stage IV/recurrent non-small cell lung cancer.

In this MEDtalk, Eric J. Small, MD and principal investigator of the SPARTAN study describes what characterizes the group of patients with non-metastatic castration-resistant prostate cancer.

In this MEDtalk, Eric J. Small, MD and principal investigator of the SPARTAN study, explains the clinical benefits from early treatment of patients with non-metastatic castration-resistant prostate cancer.

The anti-PD-L1 checkpoint inhibitor pembrolizumab has shown long-term clinical efficacy as first-line treatment in metastatic non-small cell lung cancer, as monotherapy for PD-L1-positive tumors and in combination with chemotherapy regardless of PD-L1 status.

#Tuorein julkaisu

Onkologia / Hematologia

Nro. 02 • Huhtikuu 2020
9. vuosikerta
  • AML
  • Melanooma
  • Lapsuusiän syöpä

Tweets by ASCO